The rising prevalence of benign prostatic hyperplasia (BPH) among aging men is increasing the demand for advanced surgical solutions that improve urinary function and quality of life. As healthcare providers adopt innovative treatment approaches, procedures such as transurethral resection of the prostate, laser prostate surgery, and minimally invasive BPH treatment have become the preferred options for managing moderate to severe BPH symptoms. These procedures offer effective symptom relief while reducing complications, shortening hospital stays, and enabling faster patient recovery.

The U.S. Benign Prostatic Hyperplasia Surgical Treatment Market is projected to grow at a CAGR of 5.6% from 2025 to 2034, increasing from USD 753.66 million in 2025 to USD 1,232.65 million by 2034.

Understanding Benign Prostatic Hyperplasia

Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland that commonly affects men as they age. As the prostate enlarges, it can compress the urethra, leading to urinary symptoms such as frequent urination, weak urine flow, incomplete bladder emptying, urgency, and nighttime urination.

Although lifestyle modifications and medications are often used during the early stages of the condition, surgical intervention becomes necessary when symptoms become severe or when medications fail to provide sufficient relief.

Advancements in surgical technology have significantly improved treatment outcomes, allowing physicians to perform procedures with greater precision while minimizing patient discomfort.

Transurethral Resection of the Prostate Remains the Gold Standard

Transurethral resection of the prostate (TURP) has long been considered the gold standard surgical treatment for benign prostatic hyperplasia. During this procedure, surgeons remove excess prostate tissue through the urethra using a specialized resectoscope without making external incisions.

The procedure effectively relieves urinary obstruction and significantly improves urinary flow. TURP continues to be widely performed due to its long-established clinical success and favorable patient outcomes.

Key benefits include:

• Significant improvement in urinary symptoms
• Long-term treatment effectiveness
• No external surgical incision
• Short hospitalization period
• Improved quality of life

Continuous improvements in surgical instruments and visualization technologies have further enhanced the safety and efficiency of TURP procedures across healthcare facilities.

Growing Adoption of Laser Prostate Surgery

Laser prostate surgery has emerged as one of the most advanced treatment options for patients with benign prostatic hyperplasia. Laser-based procedures use concentrated laser energy to remove or vaporize excess prostate tissue while minimizing damage to surrounding structures.

Compared with conventional surgical techniques, laser prostate surgery offers several clinical advantages, including reduced bleeding, faster recovery, and lower risk of postoperative complications.

Common laser-based procedures include:

• Holmium laser enucleation of the prostate (HoLEP)
• GreenLight laser therapy
• Thulium laser procedures

These technologies are particularly beneficial for elderly patients and individuals receiving anticoagulant therapy, where minimizing surgical bleeding is an important consideration.

The increasing availability of advanced laser systems is encouraging healthcare providers to expand minimally invasive prostate treatment programs across hospitals and specialty urology centers.

Rise of Minimally Invasive BPH Treatment

The demand for minimally invasive BPH treatment continues to grow as patients seek procedures that reduce recovery time while maintaining effective symptom relief. Modern minimally invasive therapies preserve urinary function while minimizing surgical trauma.

Emerging minimally invasive options include:

• Prostatic urethral lift (PUL)
• Water vapor thermal therapy
• Aquablation therapy
• Laser-based tissue removal
• Robotic-assisted prostate procedures

These approaches typically offer:

• Faster recovery
• Reduced postoperative pain
• Lower complication rates
• Shorter hospital stays
• Earlier return to normal activities

As healthcare providers increasingly focus on patient-centered care, minimally invasive technologies are expected to become the preferred treatment approach for many BPH patients.

US Benign Prostatic Hyperplasia Surgical Treatment Market Driving Innovation

The US Benign Prostatic Hyperplasia Surgical Treatment Market continues to expand due to increasing awareness of prostate health, technological advancements, and growing demand for effective surgical management of urinary disorders. The market includes a wide range of surgical devices, laser systems, implants, and minimally invasive treatment platforms designed to improve patient outcomes.

Several factors are supporting market growth, including:

• Rising prevalence of benign prostatic hyperplasia
• Growing aging male population
• Increasing preference for minimally invasive procedures
• Continuous advancements in laser technologies
• Expanding healthcare infrastructure
• Rising adoption of outpatient surgical treatments

Healthcare providers are increasingly investing in advanced surgical platforms that improve procedural precision, reduce complications, and enhance patient satisfaction. The shift toward ambulatory surgical centers is also contributing to greater accessibility of minimally invasive BPH procedures.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/us-benign-prostatic-hyperplasia-surgical-treatment-market

Key Players

• Boston Scientific Corporation
• Cleveland Clinic
• Cook Medical
• Eli Lilly and Company
• Medifocus, Inc.
• Medtronic
• PROCEPT BioRobotics Corporation
• Teleflex Incorporated
• The Johns Hopkins Hospital
• Viatris Inc.

Technological Advancements Transforming Prostate Surgery

Rapid innovation in urology is improving the effectiveness of BPH surgical treatments. High-definition imaging systems, robotic-assisted technologies, improved laser platforms, and advanced energy devices are enabling more precise prostate tissue removal while preserving surrounding anatomical structures.

Artificial intelligence and digital surgical planning are also beginning to support treatment selection and procedural optimization. These technologies help physicians personalize treatment based on prostate size, patient health status, and symptom severity.

Manufacturers continue developing next-generation surgical devices that improve efficiency, reduce procedure times, and enhance long-term clinical outcomes.

Future Outlook

The future of the U.S. Benign Prostatic Hyperplasia Surgical Treatment Market remains promising as healthcare systems increasingly prioritize minimally invasive care and improved patient outcomes. Growing demand for transurethral resection of the prostate, advanced laser prostate surgery, and innovative minimally invasive BPH treatment solutions will continue driving market expansion.

With ongoing technological advancements, increasing physician expertise, and rising awareness of prostate health, surgical treatment options for benign prostatic hyperplasia are expected to become safer, more effective, and more widely accessible. These developments will continue improving quality of life for millions of men while supporting sustained growth in the U.S. urology market.

More Trending Latest Reports By Polaris Market Research:

Special Effect Masterbatches Market

Lenalidomide Market

Foley Catheter Market

Microscope Market

Clinical Laboratory Tests Market

veterinary rapid test market

U.S. DNA Manufacturing Market

pediatric diabetes therapeutic market